ALEGLITAZAR
| Title | Journal |
|---|---|
| PPAR agonists for the treatment of cardiovascular disease in patients with diabetes. | Diabetes, obesity & metabolism 20121101 |
| Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. | ChemMedChem 20120601 |
| No evidence of QT prolongation with supratherapeutic doses of aleglitazar. | Journal of cardiovascular pharmacology 20120301 |
| Metabolism, excretion, and pharmacokinetics of [14c]-radiolabeled aleglitazar: a phase I, nonrandomized, open-label, single-center, single-dose study in healthy male volunteers. | Clinical therapeutics 20120201 |
| The cardiovascular effects of peroxisome proliferator-activated receptor agonists. | The American journal of medicine 20120201 |
| Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes. | PloS one 20120101 |
| Red carpeting the newer antidiabetics. | Journal of pharmacology & pharmacotherapeutics 20120101 |
| Selected Extracts of Chinese Herbal Medicines: Their Effect on NF-κB, PPARα and PPARγ and the Respective Bioactive Compounds. | Evidence-based complementary and alternative medicine : eCAM 20120101 |
| Effects of high dose aleglitazar on renal function in patients with type 2 diabetes. | International journal of cardiology 20110901 |
| Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk. | Expert opinion on drug metabolism & toxicology 20110601 |
| Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin. | Expert opinion on investigational drugs 20110101 |
| Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome. | Cardiovascular diabetology 20110101 |
| 'The metabolic syndrome... is dead': these reports are an exaggeration. | Cardiovascular diabetology 20110101 |
| Pharmacological and non-pharmacological interventions to influence adipose tissue function. | Cardiovascular diabetology 20110101 |
| Impaired lipid metabolism in idiopathic pulmonary alveolar proteinosis. | Lipids in health and disease 20110101 |
| Pleiotropic effects of glitazones: a double edge sword? | Frontiers in pharmacology 20110101 |
| Medicinal Chemistry and Actions of Dual and Pan PPAR Modulators. | The open medicinal chemistry journal 20110101 |
| THP-1 Macrophages and SGBS Adipocytes - A New Human in vitro Model System of Inflamed Adipose Tissue. | Frontiers in endocrinology 20110101 |
| Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus. | IDrugs : the investigational drugs journal 20101101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20101101 |
| Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study. | Clinical pharmacology and therapeutics 20100801 |
| Neuropathy, retinopathy, and glucose-lowering treatments. | Diabetes care 20100601 |
| Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20100101 |
| Transcriptional regulation of human and rat hepatic lipid metabolism by the grapefruit flavonoid naringenin: role of PPARalpha, PPARgamma and LXRalpha. | PloS one 20100101 |
| PPAR-alpha and PPAR-gamma agonists for type 2 diabetes. | Lancet (London, England) 20090711 |
| Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. | Lancet (London, England) 20090711 |
| Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes. | Bioorganic & medicinal chemistry letters 20090501 |
| A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. | Cardiovascular diabetology 20090101 |